These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27347820)

  • 1. Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats.
    Rausch-Derra LC; Rhodes L
    Am J Vet Res; 2016 Jul; 77(7):688-92. PubMed ID: 27347820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of grapiprant, a selective EP
    Lebkowska-Wieruszewska B; De Vito V; Owen H; Poapholatep A; Giorgi M
    J Vet Pharmacol Ther; 2017 Dec; 40(6):e11-e15. PubMed ID: 28459136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E
    Łebkowska-Wieruszewska B; Barsotti G; Lisowski A; Gazzano A; Owen H; Giorgi M
    N Z Vet J; 2017 Jan; 65(1):19-23. PubMed ID: 27691904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis.
    Rausch-Derra L; Huebner M; Wofford J; Rhodes L
    J Vet Intern Med; 2016 May; 30(3):756-63. PubMed ID: 27075237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs.
    Rausch-Derra LC; Huebner M; Rhodes L
    Am J Vet Res; 2015 Oct; 76(10):853-9. PubMed ID: 26413822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of grapiprant plasma and urine concentrations in horses.
    Cox S; Sommardahl C; Fortner C; Davis R; Bergman J; Doherty T
    Vet Anaesth Analg; 2020 Sep; 47(5):705-709. PubMed ID: 32439238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs.
    Nagahisa A; Okumura T
    J Vet Pharmacol Ther; 2017 Jun; 40(3):285-292. PubMed ID: 27597397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses.
    Hoffmann SL; Seminoff K; McKemie DS; Kass PH; Knych HK
    J Vet Pharmacol Ther; 2022 Sep; 45(5):467-472. PubMed ID: 35652132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs.
    Rausch-Derra LC; Rhodes L; Freshwater L; Hawks R
    J Vet Pharmacol Ther; 2016 Dec; 39(6):566-571. PubMed ID: 27027634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica).
    Kleine S; Hampton CE; Smith C; Bussieres G; Mulon PY; Seddighi R; Cox S; Smith J
    J Vet Pharmacol Ther; 2023 Sep; 46(5):269-275. PubMed ID: 37493273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis.
    Budsberg SC; Kleine SA; Norton MM; Sandberg GS
    Am J Vet Res; 2019 Nov; 80(11):1001-1006. PubMed ID: 31644340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic evaluation of grapiprant in a carrageenan-induced inflammatory pain model in the rabbit.
    De Vito V; Salvadori M; Poapolathep A; Owen H; Rychshanova R; Giorgi M
    J Vet Pharmacol Ther; 2017 Oct; 40(5):468-475. PubMed ID: 27925221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of grapiprant administered to red-tailed hawks (
    Rodriguez P; Paul-Murphy JR; Knych HK; Drazenovich TL; Hawkins MG
    Am J Vet Res; 2021 Nov; 82(11):912-919. PubMed ID: 34669491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection.
    Vito V; Saba A; Lee HK; Owen H; Poapolathep A; Giorgi M
    J Pharm Biomed Anal; 2016 Jan; 118():251-258. PubMed ID: 26580822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption of grapiprant in red-tailed hawks (Buteo jamaicensis) is decreased when administered with food.
    Rodriguez P; Paul-Murphy JR; Knych HK; Drazenovich TL; Hawkins MG
    Am J Vet Res; 2022 May; 83(6):. PubMed ID: 35524955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.
    Okumura Y; Yamagishi T; Nukui S; Nakao K
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1186-1192. PubMed ID: 28169162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed blockage of prostaglandin EP
    Abouelkheir M; Shabaan DA; Shahien MA
    Clin Exp Pharmacol Physiol; 2021 May; 48(5):791-800. PubMed ID: 33634509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
    de Salazar Alcalá AG; Gioda L; Dehman A; Beugnet F
    BMC Vet Res; 2019 Aug; 15(1):309. PubMed ID: 31464629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.
    Kirkby Shaw K; Rausch-Derra LC; Rhodes L
    Vet Med Sci; 2016 Feb; 2(1):3-9. PubMed ID: 29067176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grapiprant: A snapshot of the current knowledge.
    Sartini I; Giorgi M
    J Vet Pharmacol Ther; 2021 Sep; 44(5):679-688. PubMed ID: 34057218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.